ECSP088322A - Derivados de fenil-1,2,4-oxadiazolona, procesos para su preparación y su uso como compuestos farmacéuticos - Google Patents
Derivados de fenil-1,2,4-oxadiazolona, procesos para su preparación y su uso como compuestos farmacéuticosInfo
- Publication number
- ECSP088322A ECSP088322A EC2008008322A ECSP088322A ECSP088322A EC SP088322 A ECSP088322 A EC SP088322A EC 2008008322 A EC2008008322 A EC 2008008322A EC SP088322 A ECSP088322 A EC SP088322A EC SP088322 A ECSP088322 A EC SP088322A
- Authority
- EC
- Ecuador
- Prior art keywords
- disorders
- processes
- preparation
- derivatives
- oxadiazolona
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Virology (AREA)
- Immunology (AREA)
Abstract
La invención se refiere a derivados de fenil-1,2,4-oxadiazolona en todas sus formas estereoisoméricas y mezclas en cualquier relación, y sus sales fisiológicamente aceptables y formas tautoméricas que muestran actividad agonista de PPARdelta. Lo que se describe son compuestos de la fórmula I, (I) donde los radicales son como se han definido, y sus sales fisiológicamente aceptables y procesos para su preparación. Los compuestos son adecuados para el tratamiento y/o prevención de trastornos de metabolismo de ácidos grasos y trastornos de utilización de la glucosa así como de trastornos en los que está implicada la resistencia a la insulina y la desmielinización y otros trastornos neurodegenerativos del sistema nervioso central y periférico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05021277 | 2005-09-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP088322A true ECSP088322A (es) | 2008-04-28 |
Family
ID=35788653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2008008322A ECSP088322A (es) | 2005-09-29 | 2008-03-27 | Derivados de fenil-1,2,4-oxadiazolona, procesos para su preparación y su uso como compuestos farmacéuticos |
Country Status (23)
Country | Link |
---|---|
US (1) | US7709481B2 (es) |
EP (1) | EP1931337B1 (es) |
JP (1) | JP2009509988A (es) |
KR (1) | KR20080048504A (es) |
CN (1) | CN101272784A (es) |
AR (1) | AR056095A1 (es) |
AU (1) | AU2006299091A1 (es) |
BR (1) | BRPI0617207A2 (es) |
CA (1) | CA2624102A1 (es) |
CR (1) | CR9785A (es) |
DO (1) | DOP2006000203A (es) |
EC (1) | ECSP088322A (es) |
IL (1) | IL190231A0 (es) |
MA (1) | MA29805B1 (es) |
NO (1) | NO20081369L (es) |
NZ (1) | NZ566877A (es) |
PE (1) | PE20070620A1 (es) |
RU (1) | RU2008112198A (es) |
TN (1) | TNSN08148A1 (es) |
TW (1) | TW200806658A (es) |
UY (1) | UY29831A1 (es) |
WO (1) | WO2007039177A2 (es) |
ZA (1) | ZA200801629B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
AU2008279447A1 (en) | 2007-07-19 | 2009-01-29 | Metabolex, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders |
CL2009000782A1 (es) * | 2008-03-31 | 2010-04-30 | Metabolex Inc | Metodo que comprende un compuesto derivado de oximetilen-arilo sustituido, inhibidores de dpp-iv; y su uso en el tratamiento de la diabetes y disminucion de trigliceridos, entre otras enfermedades. |
EP2334669B1 (de) * | 2008-10-01 | 2015-12-23 | Bayer Intellectual Property GmbH | Heterocyclyl substituierte thiazole als pflanzenschutzmittel |
EP2376487B1 (de) | 2008-12-11 | 2016-01-06 | Bayer Intellectual Property GmbH | Thiazolyoximether und -hydrazone als pflanzenschutzmittel |
EP2198710A1 (de) | 2008-12-19 | 2010-06-23 | Bayer CropScience AG | Verwendung von 5-Pyridin-4yl-(1,3)Thiazole zur Bekämpfung phytopathogener Pilze |
AU2010255422B2 (en) * | 2009-06-05 | 2014-04-10 | Pfizer Inc. | 1- ( piperidin-4-yl) -pyrazole derivatives as GPR 119 modulators |
US8410127B2 (en) | 2009-10-01 | 2013-04-02 | Metabolex, Inc. | Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts |
CA2776242C (en) | 2009-10-08 | 2014-09-02 | Sanofi | Phenyloxadiazole derivatives as pgds inhibitors |
BR112012027762B1 (pt) | 2010-04-28 | 2018-06-05 | Bayer Intellectual Property Gmbh | Derivados de cetoheteroarilpiperidina e - piperazina como fungicidas |
BR112012032248A2 (pt) | 2010-06-23 | 2016-09-13 | Metabolex Inc | composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina |
EP2532233A1 (en) | 2011-06-07 | 2012-12-12 | Bayer CropScience AG | Active compound combinations |
KR20200127273A (ko) | 2012-04-26 | 2020-11-10 | 브리스톨-마이어스 스큅 컴퍼니 | 혈소판 응집을 치료하기 위한 프로테아제 활성화 수용체 4 (par4) 억제제로서의 이미다조티아디아졸 및 이미다조피라진 유도체 |
CA2871637A1 (en) | 2012-04-26 | 2013-10-31 | Bristol-Myers Squibb Company | Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation |
JP6101343B2 (ja) | 2012-04-26 | 2017-03-22 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 血小板凝集を治療するためのプロテアーゼ活性化受容体4(par4)阻害剤としてのイミダゾチアジアゾールおよびイミダゾピリダジン誘導体 |
WO2018026890A1 (en) | 2016-08-03 | 2018-02-08 | Cymabay Therapeutics | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5783593A (en) | 1993-11-04 | 1998-07-21 | Abbott Laboratories | Inhibitors of squalene synthetase and protein farnesyltransferase |
US5641796A (en) | 1994-11-01 | 1997-06-24 | Eli Lilly And Company | Oral hypoglycemic agents |
AU2381397A (en) | 1996-04-19 | 1997-11-12 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
WO1997041097A2 (en) | 1996-12-31 | 1997-11-06 | Dr. Reddy's Research Foundation | Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
JP4253126B2 (ja) | 1998-01-29 | 2009-04-08 | アムジェン インコーポレイテッド | Ppar−ガンマ調節剤 |
US6221897B1 (en) | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
DE19845405C2 (de) | 1998-10-02 | 2000-07-13 | Aventis Pharma Gmbh | Arylsubstituierte Propanolaminderivate und deren Verwendung |
PT1169312E (pt) | 1999-03-29 | 2005-01-31 | Hoffmann La Roche | Activadores de glicocinase |
DE19916108C1 (de) | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
EP1177187B1 (en) | 1999-04-28 | 2007-07-25 | Sanofi-Aventis Deutschland GmbH | Di-aryl acid derivatives as ppar receptor ligands |
JP2002543065A (ja) | 1999-04-28 | 2002-12-17 | アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ppap受容体リガンドとしてのトリアリール酸誘導体 |
DE60032898T2 (de) * | 1999-06-18 | 2007-10-25 | Merck & Co., Inc. | Arylthiazolidindion- und aryloxazolidinderivate |
GB9914977D0 (en) | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
CA2383781A1 (en) | 1999-09-01 | 2001-03-08 | Aventis Pharma Deutschland Gmbh | Sulfonyl carboxamide derivatives, method for their production and their use as medicaments |
GB9921684D0 (en) | 1999-09-15 | 1999-11-17 | Zeneca Ltd | Assays |
US6353111B1 (en) | 1999-12-15 | 2002-03-05 | Hoffmann-La Roche Inc. | Trans olefinic glucokinase activators |
CN1176915C (zh) | 2000-05-03 | 2004-11-24 | 霍夫曼-拉罗奇有限公司 | 炔基苯基芳香杂环的菊糖激酶激活剂 |
CA2407428C (en) | 2000-05-03 | 2010-02-02 | F. Hoffmann-La Roche Ag | Hydantoin-containing glucokinase activators |
JP3839723B2 (ja) | 2000-05-08 | 2006-11-01 | エフ.ホフマン−ラ ロシュ アーゲー | 置換フェニルアセトアミドおよびグルコキナーゼ活性化剤としてのその使用 |
WO2001085707A1 (en) | 2000-05-08 | 2001-11-15 | F. Hoffmann-La Roche Ag | Para-amine substituted phenylamide glucokinase activators |
KR100556323B1 (ko) | 2000-07-20 | 2006-03-03 | 에프. 호프만-라 로슈 아게 | 알파-아실 및 알파-헤테로원자-치환된 벤젠 아세트아미드글루코키나제 활성화제 |
US6369232B1 (en) | 2000-08-15 | 2002-04-09 | Hoffmann-La Roche Inc. | Tetrazolyl-phenyl acetamide glucokinase activators |
ES2256340T3 (es) | 2000-12-06 | 2006-07-16 | F. Hoffmann-La Roche Ag | Activadores heteroaromaticos fusionados de la glucoquinasa. |
US6482951B2 (en) | 2000-12-13 | 2002-11-19 | Hoffmann-La Roche Inc. | Isoindolin-1-one glucokinase activators |
DE10102322A1 (de) | 2001-01-19 | 2002-07-25 | Merck Patent Gmbh | Phenylderivate |
TWI291957B (en) | 2001-02-23 | 2008-01-01 | Kotobuki Pharmaceutical Co Ltd | Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same |
DE10112768A1 (de) | 2001-03-16 | 2002-09-19 | Merck Patent Gmbh | Phenylderivate 3 |
GB0111523D0 (en) | 2001-05-11 | 2001-07-04 | Glaxo Group Ltd | Chemical compounds |
SE0102300D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
US7265137B2 (en) * | 2001-08-10 | 2007-09-04 | Nippon Chemiphar Co., Ltd. | Activator of peroxisome proliferator-activated re-ceptor δ |
SE0102764D0 (sv) * | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
PT1425014E (pt) | 2001-08-31 | 2007-03-30 | Sanofi Aventis Deutschland | Derivados diarilcicloalquilo, processo para a sua preparação como activadores de ppar |
AU2002347985A1 (en) | 2001-11-15 | 2003-06-10 | Eli Lilly And Company | Peroxisome proliferator activated receptor alpha agonists |
US6911545B2 (en) | 2001-12-19 | 2005-06-28 | Hoffman-La Roche Inc. | Crystals of glucokinase and methods of growing them |
JP2005518391A (ja) | 2001-12-21 | 2005-06-23 | ノボ ノルディスク アクティーゼルスカブ | Gk活性化剤としてのアミド誘導体 |
WO2003074495A1 (en) | 2002-03-01 | 2003-09-12 | Smithkline Beecham Corporation | Hppars activators |
EP1496052B1 (en) | 2002-03-26 | 2009-08-05 | Banyu Pharmaceutical Co., Ltd. | Novel aminobenzamide derivative |
DE10215907A1 (de) | 2002-04-11 | 2003-11-06 | Aventis Pharma Gmbh | Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung |
MXPA04010605A (es) | 2002-04-26 | 2004-12-13 | Hoffmann La Roche | Fenilacetamidas substituidas y su uso como activadores de flucoquinasa. |
AU2003235307A1 (en) | 2002-05-16 | 2003-12-02 | Banyu Pharmaceutical Co., Ltd. | Crystal of glucokinase protein, and method for drug design using the crystal |
MXPA05000130A (es) | 2002-06-27 | 2005-02-17 | Novo Nordisk As | Derivados de aril-carbonilo como agentes terapeuticos. |
MXPA05000053A (es) | 2002-07-12 | 2005-04-08 | Aventis Pharma Gmbh | Benzoilureas heterociclicamente sustituidas, metodo para su produccion y su uso como medicamentos. |
ATE374768T1 (de) | 2002-10-03 | 2007-10-15 | Hoffmann La Roche | Indole-3-carbonsaüreamide als glucokinase (gk) aktivatoren |
GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
GB0226930D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
US7132425B2 (en) | 2002-12-12 | 2006-11-07 | Hoffmann-La Roche Inc. | 5-substituted-six-membered heteroaromatic glucokinase activators |
WO2004063179A1 (en) | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Substituted arylcyclopropylacetamides as glucokinase activators |
AU2003294376A1 (en) | 2003-01-06 | 2004-08-10 | Eli Lilly And Company | Heteroaryl compounds |
WO2004072066A1 (en) | 2003-02-11 | 2004-08-26 | Prosidion Limited | Tri(cyclo) substituted amide glucokinase activator compounds |
PL378117A1 (pl) | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
AR045414A1 (es) | 2003-02-13 | 2005-10-26 | Banyu Pharma Co Ltd | Derivados de 2 - piridincarboxamida y composiciones farmaceuticas que las contienen. |
DE10308351A1 (de) | 2003-02-27 | 2004-11-25 | Aventis Pharma Deutschland Gmbh | 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE10308352A1 (de) | 2003-02-27 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
DE10308353A1 (de) | 2003-02-27 | 2004-12-02 | Aventis Pharma Deutschland Gmbh | Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE10308356A1 (de) | 2003-02-27 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
DE10308354A1 (de) | 2003-02-27 | 2004-12-23 | Aventis Pharma Deutschland Gmbh | Cycloalkylderivate mit biosteren Carbonsäure-Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE10308355A1 (de) | 2003-02-27 | 2004-12-23 | Aventis Pharma Deutschland Gmbh | Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
WO2004080943A1 (ja) | 2003-03-11 | 2004-09-23 | Ono Pharmaceutical Co., Ltd. | シンナミルアルコール誘導体化合物およびその化合物を有効成分として含有する薬剤 |
BRPI0409763A (pt) | 2003-04-17 | 2006-05-09 | Kalypsys Inc | compostos de arila como moduladores de ppars, método de modulação, método de inibição da formação de adipócitos em um mamìfero, método de tratamento de uma doença ou uma condição modulada por ppar e composição farmacêutica |
JP2006528687A (ja) | 2003-05-09 | 2006-12-21 | メルク エンド カムパニー インコーポレーテッド | ベンズイミダゾール、こうした化合物を含有する組成物および使用方法 |
GB0325402D0 (en) | 2003-10-31 | 2003-12-03 | Astrazeneca Ab | Compounds |
EP1532980A1 (en) | 2003-11-24 | 2005-05-25 | Novo Nordisk A/S | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes |
GB0327761D0 (en) | 2003-11-29 | 2003-12-31 | Astrazeneca Ab | Compounds |
GB0327760D0 (en) | 2003-11-29 | 2003-12-31 | Astrazeneca Ab | Compounds |
WO2005054213A1 (ja) | 2003-12-02 | 2005-06-16 | Shionogi & Co., Ltd. | ペルオキシソーム増殖活性化受容体アゴニスト活性を有するイソキサゾール誘導体 |
GB0328178D0 (en) | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Compounds |
EP1699453A4 (en) | 2003-12-19 | 2009-07-01 | Merck & Co Inc | CYCLIC GUANIDINES, COMPOSITIONS AND METHOD OF ADMINISTRATION CONTAINING SUCH COMPOUNDS |
GB0329778D0 (en) | 2003-12-23 | 2004-01-28 | Astrazeneca Ab | Chemical compounds |
CN100471835C (zh) | 2003-12-23 | 2009-03-25 | 默克公司 | 抗高胆固醇血症化合物 |
BRPI0418004A (pt) | 2003-12-23 | 2007-04-17 | Astrazeneca Ab | composto ou um sal, solvato, solvato de um tal sal ou uma pró-droga deste farmaceuticamente aceitáveis, métodos para tratar ou prevenir condições hiperlipidêmicas, aterosclerose, mal de alzheimer, e tumores associados com colesterol, formulação farmacêutica, combinação, e, processo para preparar um composto ou um sal, solvato, solvato de um tal sal ou uma pró-droga deste farmaceuticamente aceitáveis |
NZ548128A (en) | 2003-12-29 | 2010-05-28 | Banyu Pharma Co Ltd | Novel 2-heteroaryl-substituted benzimidazole derivative |
ES2290782T3 (es) | 2004-01-06 | 2008-02-16 | Janssen Pharmaceutica N.V. | Derivados de (3-oxo-3,4-dihidro-quinoxalin-2-il-amino)-benzamida y compuestos aferentes como inhibidores de la glucogeno fosforilasa en el tratamiento de la diabetes y de la obesidad. |
WO2005066145A1 (en) | 2004-01-06 | 2005-07-21 | Novo Nordisk A/S | Heteroaryl-ureas and their use as glucokinase activators |
DE502005007840D1 (de) | 2004-01-31 | 2009-09-17 | Sanofi Aventis Deutschland | 7-phenylamino-4-chinolon-3-carbonsäure-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
DE102004006325A1 (de) | 2004-02-10 | 2005-08-25 | Bayer Healthcare Ag | Tetrahydrobenzo[d]azepin-2-on-Derivate und ihre Verwendung |
EP2048137A1 (en) | 2004-02-18 | 2009-04-15 | AstraZeneca AB | Benzamide derivatives and their use as glucokinase activating agents. |
KR20070007104A (ko) | 2004-02-18 | 2007-01-12 | 아스트라제네카 아베 | 화합물 |
JO2537B1 (en) | 2004-03-10 | 2010-09-05 | جانسين فارماسوتيكا ان. في | Aryl-pyridine or pyrezinate compounds replaced with heterogeneous pentagonal rings used as inhibitors of MTB proteins |
US7687502B2 (en) | 2004-03-23 | 2010-03-30 | Banyu Pharmaceutical Co., Ltd. | Substituted quinazoline or pyridopyrimidine derivative |
EP1781648A2 (en) | 2004-04-01 | 2007-05-09 | Aventis Pharmaceuticals Inc. | 1,3,4-oxadiazol-2-ones as ppar delta modulators |
DE602004004631D1 (de) | 2004-04-01 | 2007-03-22 | Sanofi Aventis Deutschland | Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika |
JP4813460B2 (ja) * | 2004-04-01 | 2011-11-09 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | PPARδモジュレーターとしての1,3,4−オキサジアゾール−2−オン及びその使用 |
US20080096922A1 (en) | 2004-04-06 | 2008-04-24 | Dainippon Sumitomo Pharma Co., Ltd. | Novel Sulfonamide derivative |
US20080242869A1 (en) | 2004-04-21 | 2008-10-02 | Matthew Fyfe | Tri(Cyclo) Substituted Amide Compounds |
WO2005111003A1 (en) | 2004-04-29 | 2005-11-24 | Abbott Laboratories | Amino-tetrazoles analogues and methods of use |
TW200600086A (en) | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
WO2005123132A2 (en) | 2004-06-17 | 2005-12-29 | Novo Nordisk A/S | Use of liver-selective glucokinase activators |
GB0418046D0 (en) | 2004-08-12 | 2004-09-15 | Prosidion Ltd | Eantioselective process |
DE102004039533B4 (de) | 2004-08-14 | 2006-09-28 | Sanofi-Aventis Deutschland Gmbh | Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
DE102004039532B4 (de) | 2004-08-14 | 2006-09-21 | Sanofi-Aventis Deutschland Gmbh | Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
DE102004039509B4 (de) | 2004-08-14 | 2006-09-21 | Sanofi-Aventis Deutschland Gmbh | Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
EP1794159B1 (en) | 2004-09-11 | 2012-08-01 | Sanofi-Aventis Deutschland GmbH | 7-azaindoles and their use as ppar agonists |
DE102005033100B3 (de) | 2005-07-15 | 2007-01-25 | Sanofi-Aventis Deutschland Gmbh | Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung |
DE102005033099A1 (de) | 2005-07-15 | 2007-01-18 | Sanofi-Aventis Deutschland Gmbh | Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung |
-
2006
- 2006-09-26 WO PCT/EP2006/009303 patent/WO2007039177A2/en active Application Filing
- 2006-09-26 BR BRPI0617207-5A patent/BRPI0617207A2/pt not_active IP Right Cessation
- 2006-09-26 EP EP06792251.8A patent/EP1931337B1/en active Active
- 2006-09-26 KR KR1020087007393A patent/KR20080048504A/ko not_active Application Discontinuation
- 2006-09-26 CA CA002624102A patent/CA2624102A1/en not_active Abandoned
- 2006-09-26 RU RU2008112198/04A patent/RU2008112198A/ru not_active Application Discontinuation
- 2006-09-26 AU AU2006299091A patent/AU2006299091A1/en not_active Abandoned
- 2006-09-26 NZ NZ566877A patent/NZ566877A/en not_active IP Right Cessation
- 2006-09-26 JP JP2008532647A patent/JP2009509988A/ja not_active Abandoned
- 2006-09-26 CN CNA2006800359361A patent/CN101272784A/zh active Pending
- 2006-09-27 DO DO2006000203A patent/DOP2006000203A/es unknown
- 2006-09-27 TW TW095135658A patent/TW200806658A/zh unknown
- 2006-09-27 AR ARP060104223A patent/AR056095A1/es not_active Application Discontinuation
- 2006-09-27 PE PE2006001170A patent/PE20070620A1/es not_active Application Discontinuation
- 2006-09-29 UY UY29831A patent/UY29831A1/es not_active Application Discontinuation
-
2008
- 2008-02-19 ZA ZA200801629A patent/ZA200801629B/xx unknown
- 2008-02-29 CR CR9785A patent/CR9785A/es not_active Application Discontinuation
- 2008-03-14 NO NO20081369A patent/NO20081369L/no not_active Application Discontinuation
- 2008-03-17 IL IL190231A patent/IL190231A0/en unknown
- 2008-03-24 MA MA30781A patent/MA29805B1/fr unknown
- 2008-03-26 US US12/055,780 patent/US7709481B2/en not_active Expired - Fee Related
- 2008-03-27 EC EC2008008322A patent/ECSP088322A/es unknown
- 2008-03-28 TN TNP2008000148A patent/TNSN08148A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2007039177A3 (en) | 2007-09-07 |
NZ566877A (en) | 2010-05-28 |
CR9785A (es) | 2008-05-21 |
ZA200801629B (en) | 2009-03-25 |
US7709481B2 (en) | 2010-05-04 |
EP1931337A2 (en) | 2008-06-18 |
MA29805B1 (fr) | 2008-09-01 |
BRPI0617207A2 (pt) | 2011-07-19 |
AR056095A1 (es) | 2007-09-19 |
PE20070620A1 (es) | 2007-07-10 |
US20080261979A1 (en) | 2008-10-23 |
WO2007039177B1 (en) | 2007-11-01 |
DOP2006000203A (es) | 2007-06-30 |
NO20081369L (no) | 2008-05-28 |
TNSN08148A1 (en) | 2009-07-14 |
AU2006299091A1 (en) | 2007-04-12 |
EP1931337B1 (en) | 2013-10-23 |
KR20080048504A (ko) | 2008-06-02 |
CN101272784A (zh) | 2008-09-24 |
WO2007039177A2 (en) | 2007-04-12 |
CA2624102A1 (en) | 2007-04-12 |
RU2008112198A (ru) | 2009-10-10 |
IL190231A0 (en) | 2008-11-03 |
TW200806658A (en) | 2008-02-01 |
UY29831A1 (es) | 2007-04-30 |
JP2009509988A (ja) | 2009-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP088322A (es) | Derivados de fenil-1,2,4-oxadiazolona, procesos para su preparación y su uso como compuestos farmacéuticos | |
ECSP088323A (es) | Derivados de fenil-[1,2,4]-oxadiazol-5-ona con grupo fenilo, procedimientos para su preparación y su uso como productos farmacéuticos | |
ECSP099409A (es) | Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona, procedimientos para su preparación y su uso como agentes farmacéuticos | |
ECSP066892A (es) | Derivados de oxadiazolona como agonistas de ppar delta | |
UY31872A (es) | Sulfonamidas n-heterocíclicas aneladas con grupo de cabeza de oxadiazolona, procesos para su preparación y su uso como sustancias farmacéuticas | |
ECSP066391A (es) | [1,8] naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia | |
UY31873A (es) | Pirrolidin sulfonamidas aneladas con grupo de cabeza de oxadiazolona, procesos para su preparación y su uso como sustancias farmacéuticas | |
UY28990A1 (es) | Nuevos derivados de benceno 1, 3-amino carbonilo como inhibidores de b-raf, composiciones farmacéuticas que los contienen, procesos de preparación y uso. | |
ECSP077275A (es) | Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos | |
UY29300A1 (es) | Compuestos quimicos | |
UY28732A1 (es) | Derivados de acido 7-fenilamino-4-quinolona-3-carboxilico, procesos para su preparación y su uso como medicamentos. | |
UY30547A1 (es) | Derivados n-sustituidos de la 6-piridin-4-il quinazolin-2-amina, sus estereoisomeros y sales farmacéuticamente aceptables, proceso de preparacion, composiciones y aplicaciones. | |
UY30282A1 (es) | Compuestos quimicos | |
CL2008001820A1 (es) | Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer. | |
UY28210A1 (es) | Derivados de ácido acético sustituido con cicloalquilmetoxi, procedimientos para su preparacion y su uso como farmacos. | |
UY31874A (es) | Sulfonamidas con grupo de cabeza de heterociclo y oxadiazolona, procesos para su preparación y su uso como sustancias farmacéuticas | |
UY29846A1 (es) | N-(1,3,4)-tiadiazol-2-il-bencensulfonamidas, procesos para su preparación y su uso como productos farmacéuticos | |
UY29847A1 (es) | N-(1,3,4)-tiadiazol-2-il-bencensulfonamidas cíclicas, procesos para su preparación y su uso como productos farmacéuticos. | |
UY30880A1 (es) | 7-alcoxicinolin-3-carboxamidas sustituidas y sales farmacéuticamente aceptables de las mismas, procedimientos de preparacion y aplicaciones | |
UY27998A1 (es) | Piperazinas sustituidas sustituidas heterocíclicas para el tratamiento de la esquizofrenia | |
UY29848A1 (es) | (1,3,4)-tiadiazol-2-il-amidas bicíclicas del ácido aril-sulfónico, procesos para su preparación y su uso como productos farmacéuticos | |
UY29832A1 (es) | Derivados de 2-aminotiazoles y 2-aminooxazoles, procesos para su preparación y su uso como compuestos farmacéuticos. | |
UY30699A1 (es) | Derivados sustituidos de 4-fenilamino-quinolina-3-carboxamidas, sales farmacéuticamente aceptables, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
UY29849A1 (es) | 4-oxi-n-(1.3.4)-tiadiazol-2-il-bencenosulfonamidas, procesos para su preparación y su uso como productos farmacéuticos. | |
UY28208A1 (es) | Derivados cicloalquilo que tienen grupos acido carboxilico bioisostéricos, procesos para su preparación y su uso como composiciones farmaceuticas. |